Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-05-23
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, multicenter, dose-escalation/dose-expansion study of YBL-006,
in participants with Advanced Solid Tumors. This multicenter study will be conducted in
approximately 11-14 participants in the dose escalation phase, and approximately 39-76
participants in dose expansion phase.